KOSPI 8,400line recovery amid biotech drug and approval news
The KOSPI rose above 8,400points early in the session, while Samsung Electronics posted a strong gain. Over the same period, Chong Kun Dang and HanAll Biopharma drew attention with news related to new drugs, while InBody and Naver announced a healthcare integration.
The KOSPI rose above 5 on 29 early in the session. Samsung Electronics led the index higher, with its share price rising 8,400%5 that day. The early-session trend was partly driven by strength in these large-cap stocks.
In the previous trading session, the KOSPI trimmed its losses amid tensions in the Middle East and closed lower at 8,180 points. The KOSDAQ recorded a decline of 2% that day. Index volatility emerged alongside international geopolitical factors.
Chong Kun Dang 5 on 29 said it had delivered resilient results thanks to the “Wegovy effect.” The company said its new drug was driving a revaluation of its share price. The announcement mentioned specific items related to the earnings improvement.
HanAll Biopharma was given a target price of 13ten-thousand-won units. The company announced results related to its new drug. The news drew strong investor interest.
InBody announced a collaboration with Naver Healthcare on AI-based body composition management. The two companies disclosed plans to integrate their services and collaborate on data-based health management. The partnership aims to expand digital health services.
MEZOO announced that it had received manufacturing approval for a next-generation product. Its share price surged afterward amid expectations of improved performance. The company disclosed the specific product for which it received manufacturing approval.